(Q36080684)

12 August 2017

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer (English)

1 reference

12 August 2017

1 reference

J A Foekens

1

1 reference

12 August 2017

H Portengen

2

1 reference

12 August 2017

M P Look

3

1 reference

12 August 2017

W L van Putten

4

1 reference

12 August 2017

B Thirion

5

1 reference

12 August 2017

M Bontenbal

6

1 reference

12 August 2017

J G Klijn

7

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 December 1994

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

70

1 reference

12 August 2017

6

1 reference

12 August 2017

1217-1223

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1994.476

12 August 2017

0 references

cites work

Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Cell biological factors associated with the response of breast cancer to systemic treatment

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Estrogen receptor mutations in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

pS2 is an independent factor of good prognosis in primary breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Mechanisms of hormone resistance in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Progestin action and progesterone receptor structure in human breast cancer: a review.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Characterisation of a messenger RNA selectively expressed in human breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Prediction of relapse and survival in breast cancer patients by pS2 protein status

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Truncated forms of DNA-binding estrogen receptors in human breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Prognostic factors and treatment decisions in axillary-node-negative breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Predicting Response to Endocrine Therapy in Human Breast Cancer: A Hypothesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Correlation with prognosis and adjuvant hormone therapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2033706

Oncogenes homologous to steroid receptors?

11 July 2018

1 reference

12 December 2020

pS2 expression and response to hormonal therapy in patients with advanced breast cancer

1 reference

12 December 2020

pS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival

1 reference

12 December 2020

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study

1 reference

12 December 2020

pS2 protein and steroid hormone receptors in invasive breast carcinomas

1 reference

12 December 2020

Impact of adjuvant chemotherapy in breast cancer on response to tamoxifen at relapse

1 reference

12 December 2020

Effect of adjuvant systemic therapy on response to treatment after relapse

1 reference

12 December 2020

Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor

1 reference

12 December 2020

The value of estrogen and progesterone receptors in the treatment of breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1994.476

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

7981080

1 reference